News

Morgan Stanley raises base case 2025 yr-end S&P 500 target to 6,500

Morgan Stanley has increased its 12-month base case price target on the S&P 500 to 6,500, the firm's equity strategist Michael Wilson and other strategists wrote in a note on Monday. According to the note, the firm expects the recent broadening in U.S. earnings growth to continue in 2025 as the Federal Reserve cuts interest rates into next year and as business cycle indicators improve further. "A potential rise in corporate animal spirits post the election (as we saw following the 2016 election) could catalyze a more balanced earnings profile across the market in 2025," the strategists added.

Wall Street Teams With BlackRock to Provide Bond Price Data

(Bloomberg) -- Some of Wall Street’s biggest banks are teaming up with BlackRock Inc.’s Aladdin technology system to provide real-time pricing data for trading US corporate bonds – still one of the most opaque areas in financial markets.Most Read from BloombergIn Cleveland, a Forgotten Streetcar Bridge Gets a Long-Awaited LiftParis to Replace Parking Spaces With TreesAmtrak Wins $300 Million to Fix Its Unreliable NJ-to-NYC ServiceA Bug’s Eye View of Mexico City’s Modernist ArchitectureNew York’s

Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps

On Monday, Twist Bioscience Corporation (NASDAQ:TWST) reported a fourth-quarter loss per share of 59 cents, beating the consensus loss of 70 cents. Twist Bioscience reported fourth-quarter sales of $84.71 million, up 27% year-over-year, beating the consensus of $82.2 million and the management guidance of $82 million–$83 million. The company shipped products to approximately 3,562 customers in fiscal 2024, compared to approximately 3,450 in 2023. Twist shipped approximately 772,000 genes in 2024